News Lobe Sciences acquires rare blood disease treatment company Lobe's primary focus is psychedelic medicines but the company also has an interest in treating rare disorders Rowan DunneApril 18, 2023
Psychedelics Woke Pharma and Swinburne U partner for Australia’s biggest psilocybin trial The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression Rowan DunneFebruary 1, 2023
Research Lobe Sciences partners with iNGENū for new clinical trials in Australia Canadian biopharmaceutical company will receive government tax incentive for studies down under Rowan DunneAugust 12, 2022